Pluristem (PSTI) Receives Approval to Commence PLX-PAD Phase II in Germany
- Top 10 News for 7/27 - 7/31: Teva Makes it Official with Allergan; China Stock Slide Continues; Revised Q2 GDP Misses Mark
- ExxonMobil (XOM) Posts Q2 EPS of $1.00
- TerraForm Global (GLBL) IPO Opens at $14
- Unusual 11 Mid-Day Movers 7/31: (YRCW) (MGI) (HTCH) Higher; (EYEG) (RADA) (OCN) Lower
- UPS (UPS) to Acquire Coyote Logistics in $1.8B Deal
Pluristem Therapeutics, Inc. (Nasdaq: PSTI) announced that the Paul-Ehrlich-Institute (PEI), the medical regulatory body for biological medicinal products for the Federal Republic of Germany, has approved the company's request to initiate a Phase II study using PLX-PAD cells in patients suffering from Intermittent Claudication (IC). IC is a subset of Peripheral Artery Disease (PAD). According to The SAGE Group and HCUP 2007 Inpatient Data, the prevalence of IC in the United States is approximately 14 million patients, representing a cost of approximately $2.5 billion annually to the healthcare system.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Horizon Pharma (HZNP) Receives Notice of Allowance from USPTO for PENNSAID-Related Patent
- Outerwall (OUTR) Names Erik Prusch as CEO
- Maxim Group Keeps ADMA Biologics (ADMA) at 'Buy' Following RI-002 BLA Submission; Sees Approval in Q316
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!